CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .
Consensus on a core set of domains for psoriatic arthritis.
A  psoriatic arthritis ( PsA ) module was convened at OMERACT 8 in order to achieve consensus on the core domains that should be included in r and omized controlled trials and longitudinal observational cohorts of subjects with PsA. Following a plenary session at which current status of measures used to assess PsA were review ed , and discussion at breakout groups , the group achieved consensus on 6 core domains : peripheral joint activity , skin activity , pain , patient global assessment , physical function , and health-related quality of life . In addition the following domains were considered important but not m and atory : spinal disease , dactylitis , enthesitis , fatigue , nail disease , radiography , physician global assessment , and acute-phase reactants . A research agenda was proposed to include development and validation of instruments for the domains where none existed , and in particular further research was recommended for the following areas : magnetic resonance imaging and ultrasound of joints , enthesitis , skin and synovial tissue analysis , and " participation .
CONCLUSIONS At least one PROM with some evidence for aspects of validity and reliability was available for six of the eight m and atory domains of the PsA COS
BACKGROUND An up date d psoriatic arthritis ( PsA ) core outcome set ( COS ) for r and omized controlled trials ( RCTs ) was endorsed at the Outcome Measures in Rheumatology ( OMERACT ) meeting in 2016 .
OBJECTIVES To synthesize the evidence on measurement properties of patient reported outcome measures ( PROMs ) for PsA and thereby contribute to development of a PsA core outcome measurement set ( COMS ) as described by the OMERACT Filter 2.0 .